64
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study

Pages 281-288 | Published online: 09 Jun 2010

References

  • AllenMHCurrierGWHughesDHReyes-HardeMDochertyJPExpert Consensus Panel for Behavioral EmergenciesThe Expert Consensus Guideline Series: treatment of behavioral emergenciesPostgrad Med.2001;(Spec No):18811500996
  • KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull1987132612763616518
  • BakerRWKinonBJMaguireGAEffectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitationJ Clin Psychopharmacol20032334234812920409
  • HattaKTakahashiTNakayamaHAbnormal physiological conditions in acute schizophrenic patients on emergency admission; dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymesEur Arch Psychiatry Clin Neurosci19982481801889810481
  • BarthEAlbusziesGBaumgartKGlucose metabolism and catecholaminesCrit Care Med200735S50851817713401
  • NewcomerJWMetabolic considerations in the use of antipsychotic medications: a review of recent evidenceJ Clin Psychiatry200768202717286524
  • NagamineTEffects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patientsNeuropsychiatr Dis Treat2008448148618728746
  • McEvoyJPMeyerJMGoffDCPrevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophr Res200580193216137860
  • RaalFJPathogenesis and management of the dyslipidemia of the metabolic syndromeMetab Syndr Relat Disord20097838819400742
  • MeyerJMDavisVGMcEvoyJPImpact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Schizophr Res200810310410918534821
  • CorrellCUFredericksonAMKaneJMDoes antipsychotic polypharmacy increase the risk for metabolic syndromeSchizophr Res2007899110017070017
  • MelkersonKSerum creatinine kinase levels in chronic psychosis patients; a comparison between atypical and conventional antipsychoticsProg Neurop Sychopharm Biol Psychiatry20063012771282